Addendum. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: <i>Standards of Care in Diabetes—2023</i>. Diabetes Care 2023;46(Suppl. 1):S41–S48
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana Isaacs, Eric L. Johnson, Scott Kahan, Kamlesh Khunti, José León, Sarah K. Lyons, Mary Lou Perry, Priya Prahalad, Richard E. Pratley, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Abstract
Section 3, "Prevention or Delay of Type 2 Diabetes and Associated Comorbidities," of the Standards of Care in Diabetes—2023 has been updated based on recent U.S. Food and Drug Administration approval of a new drug to delay the incidence of type 1 diabetes.
Topics & Concepts
MedicineDiabetes mellitusType 2 diabetesAddendumFood and drug administrationIncidence (geometry)GerontologyInternal medicineIntensive care medicineEndocrinologyEnvironmental healthPhysicsPolitical scienceLawOpticsDiabetes Management and ResearchDiabetes and associated disordersDiabetes Treatment and Management